Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-7 Recombinant Protein (ECD-Fc / Monomer) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View IL7 Products |
| Gene Delivery | IL-7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View IL7 Products |
| Benchmark Ab | Anti-IL-7 (Sequence of Efinesokin Alpha / NT-I7) Recombinant positive control antibody for benchmark assays. |
View IL7 Products |
| Validator | IL-7 siRNA Set For target knockdown verification and specificity controls. |
View IL7 Products |
| Related Target A | IL-7R (CD127) Primary receptor subunit initiating the IL-7 signaling cascade. Essential for binding assays. |
View IL7R Products |
| Related Target B | IL2RG (CD132) Common gamma chain accessory protein required for functional IL-7 receptor complex formation. |
View IL2RG Products |
| Related Target C | PD-L1 (CD274) Synergistic pathway target; co-targeting IL-7 and PD-L1 reverses T-cell exhaustion in solid tumors. |
View CD274 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog IL-7 and IL-7R proteins available with >95% purity. |
| Receptor heterodimerization validation | High-purity IL-7R (CD127) and IL2RG (CD132) monomeric and Fc-fusion proteins strictly verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity and knock-down checks. |
Live IL-7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-7 therapeutics is intensifying, with major players shifting focus from traditional recombinant cytokines to long-acting Fc-fusions and bispecific fusion proteins. As first-generation therapies reach late-stage clinical trials, the next wave of R&D is targeting the tumor microenvironment (TME) to boost CAR-T cell persistence and reverse checkpoint-inhibitor resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting Cytokine (Fc-Fusion) | NeoImmuneTech (NT-I7), Clinigen | Solid Tumors, Lymphopenia, Sepsis | In vitro bioactivity & binding kinetics (Need high-purity CD127 and CD132) |
| Bispecific Fusion Proteins (e.g., PD-L1/IL-7) | Merck KGaA, Hengrui Medicine | CPI-Refractory Solid Tumors | Simultaneous binding assays (Need CD274 and IL-7R target panels) |
| CAR-T Co-expression (IL-7/CCL19) | Noile-Immune Biotech | Solid Tumors (CAR-T persistence) | In vitro validation of CAR-T proliferation (Need recombinant IL-7 and target verification siRNA) |